Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

NCT03211234 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: 2.0 mg DE-122 Injectable Solution + Lucentis
DRUG: 4.0 mg DE-122 Injectable Solution + Lucentis
DRUG: Lucentis

Sponsor

Santen Inc.